NCT05590468

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

Randomized, Double-blinded, Placebo-controlled Study Evaluating the Efficacy of Nicotinamide Riboside (NR) - a Vitamin B3 Derivative - for Treatment of Mitochondrial Myopathy Disorder

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Ralitza Gavrilova · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplement in adult-onset symptoms of mitochondrial myopathy.

Conditions

• Mitochondrial Myopathy

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Nicotinamide Riboside	Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
DRUG	Placebo	Looks exactly like the study drug, but it contains no active ingredient

Timeline

• Start date: 2023-05-26
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2022-10-21
• Last updated: 2026-01-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study